{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(8)"],"submitter":["Hsieh TC"],"pubmed_abstract":["<h4>Introduction</h4>This study examined the association between metformin-based oral antihyperglycemic combination therapy and the risk of developing dementia in patients with newly diagnosed type 2 diabetes mellitus (T2DM).<h4>Methods</h4>We conducted a retrospective cohort study using data from a random sample of 2,000,000 individuals in Taiwan's National Health Insurance Research Database from 2000 to 2018. A total of 44,073 patients with newly diagnosed T2DM were identified and categorized into four groups based on initial treatment: metformin (MET)-sulfonylureas (SU), MET-dipeptidyl peptidase-4 inhibitor (DPP4i), MET-thiazolidinedione (TZD), and MET-glinides. The participants were followed until December 2018.<h4>Results</h4>The hazard ratio of MET-TZD was 0.73 (95% confidence interv"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pagination":["e70590"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12358239"],"repository":["biostudies-literature"],"pubmed_title":["Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study."],"pmcid":["PMC12358239"],"pubmed_authors":["Hsieh TC","Chen HH","Chang WC","Ho CP"],"additional_accession":[]},"is_claimable":false,"name":"Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.","description":"<h4>Introduction</h4>This study examined the association between metformin-based oral antihyperglycemic combination therapy and the risk of developing dementia in patients with newly diagnosed type 2 diabetes mellitus (T2DM).<h4>Methods</h4>We conducted a retrospective cohort study using data from a random sample of 2,000,000 individuals in Taiwan's National Health Insurance Research Database from 2000 to 2018. A total of 44,073 patients with newly diagnosed T2DM were identified and categorized into four groups based on initial treatment: metformin (MET)-sulfonylureas (SU), MET-dipeptidyl peptidase-4 inhibitor (DPP4i), MET-thiazolidinedione (TZD), and MET-glinides. The participants were followed until December 2018.<h4>Results</h4>The hazard ratio of MET-TZD was 0.73 (95% confidence interv","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-13T17:07:21.278Z","creation":"2026-04-07T13:36:55.619Z"},"accession":"S-EPMC12358239","cross_references":{"pubmed":["40820069"],"doi":["10.1002/alz.70590"]}}